Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Cemiplimab Displays Survival Benefits Over Chemotherapy in First-Line Advanced PD-L1–High NSCLC With Brain Metastases

May 17th 2025

First-line cemiplimab extended median PFS and OS vs chemotherapy in patients with untreated advanced NSCLC with brain metastases.

European Commission Approves Perioperative Nivolumab and Chemotherapy for Resectable PD-L1+ NSCLC

May 16th 2025

Perioperative nivolumab plus chemotherapy was approved by the European Commission for use in resectable PD-L1–positive non–small cell lung cancer.

The Impact of Frontline Treatment Selection on Second-line Therapy for EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how many patients never receive second-line therapy, emphasizing the critical importance of selecting the optimal first-line treatment and monitoring patients closely to identify progression early.

Disease Reassessment at First Progression and Treatment Options for Resistance Mechanisms in EGFR-mutant NSCLC

May 16th 2025

Panelists discuss how subsequent therapy after initial disease progression should consider patient symptomatology, biomarker testing through tissue or liquid biopsies, and potential treatment options including MET-targeted approaches or chemotherapy combinations.

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

May 15th 2025

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

FDA Green Lights Companion Diagnostic for Telisotuzumab Vedotin in NSCLC

May 15th 2025

The FDA has approved the VENTANA MET (SP44) RxDx Assay as a companion diagnostic for telisotuzumab vedotin in non–small cell lung cancer.

Lung Cancer Experts Highlight the Most Anticipated Abstracts at the 2025 ASCO Annual Meeting

May 15th 2025

Ahead of the 2025 ASCO Annual Meeting, lung cancer experts highlight the abstracts and related trials they’re looking forward to seeing at the meeting.

FDA Grants Accelerated Approval to Telisotuzumab Vedotin In Pretreated Advanced NSCLC With c-MET Overexpression

May 14th 2025

The FDA approved telisotuzumab vedotin for pretreated advanced NSCLC harboring high c-MET protein overexpression.

Rhenium (Re186) Obisbemeda Shows Initial Safety, Clinical Benefit in Leptomeningeal Metastases

May 14th 2025

The novel injectable radiotherapy 186RNL showed safety and clinical activity as treatment for patients with leptomeningeal metastases.

Evolving Targeted Therapy Approaches in Resectable Early-Stage NSCLC With Actionable Mutations

May 14th 2025

Panelists discuss how medical professionals are integrating targeted therapies, such as those for EGFR, ALK, and other mutations like RET and ROS1, into the treatment of resectable early-stage non–small cell lung cancer (NSCLC), with a focus on incorporating the ADAURA and ALINA regimens into clinical practice.

Expert Insights and Clinical Decision-Making: Neoadjuvant and Perioperative Strategies in Early-Stage NSCLC

May 14th 2025

Panelists discuss how medical professionals identify patients who should receive neoadjuvant immune checkpoint inhibitors (ICI) before surgery based on tumor characteristics, patient health, and treatment response, and how factors such as surgical outcomes, recurrence risk, and molecular markers guide decisions on the need for additional adjuvant therapy post surgery.

Dr Chiappori on the Role of Ensartinib for ALK+ NSCLC With CNS Metastases

May 13th 2025

Alberto Chiappori, MD, discusses the inclusion of patients with CNS metastases in the eXALT3 trial of ensartinib in ALK-positive NSCLC.

Frontline Belrestotug Plus Dostarlimab Misses PFS End Point in PD-L1–High NSCLC

May 13th 2025

Belrestotug plus dostarlimab did not improve PFS vs dostarlimab monotherapy in PD-L1–high NSCLC, supporting the termination of belrestotug development.

Dr Murray on the Safety of Encorafenib/Binimetinib and Dabrafenib/Trametinib in BRAF V600E+ NSCLC

May 12th 2025

Joseph C. Murray, MD, PhD, discusses the safety profiles of encorafenib/binimetinib and dabrafenib/trametinib in patients with BRAF V600E–mutant NSCLC.

Five Under 5: Top Oncology Videos for the Week of 5/4

May 11th 2025

The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 5/4

May 10th 2025

A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.

Poll Results Punctuate Key Lung Cancer Abstracts Driving Intrigue Ahead of ASCO 2025

May 9th 2025

Poll results highlighted key lung cancer abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

The Importance of Quality of Life in Treatment Decision-Making for EGFR-Mutant NSCLC

May 9th 2025

Panelists discuss how quality of life considerations, including prophylactic medications to prevent dermatologic toxicities and infusion-related reactions, are crucial when implementing EGFR-targeted therapies, especially the MARIPOSA regimen.

SOC Encorafenib/Binimetinib Sets a Precedent for Therapeutic Improvements in BRAF V600E–Mutant NSCLC

May 9th 2025

Joseph C. Murray, MD, highlights positive treatment shifts that have shaped the BRAF V600E–mutant non–small cell lung cancer treatment paradigm.

Analyzing the MARIPOSA Overall Survival Data in the Frontline Treatment of EGFR-Mutant NSCLC

May 9th 2025

Panelists discuss how the overall survival benefit from the MARIPOSA regimen (amivantamab plus lazertinib) with a hazard ratio of 0.75 and projected survival improvement exceeding 1 year represents a significant advancement that must be weighed against toxicity concerns.